CC
ADMA icon

Centiva Capital’s ADMA Biologics ADMA Stock Holding History

Centiva Capital’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,065
Closed -$201K – 1039
2025
Q2 		$201K Sell
11,065
-6,641
-38% -$135K ﹤0.01% 1342
2025
Q1 		$351K Buy
17,706
+369
+2% +$6.38K 0.01% 1002
2024
Q4 		$297K Buy
+17,337
New +$326K 0.01% 1146

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.82B AUM 73.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Centiva Capital's ADMA Position: Q3 2025 in Review

Centiva Capital sold out of ADMA Biologics (ADMA) in Q3 2025, closing a stake of 11,065 shares — an estimated $201K sold.

Centiva Capital first reported a position in ADMA in Q4 2024 and held it in 3 quarters. The position peaked at $351K in Q1 2025. 365 funds tracked by Wall St. Rank hold ADMA as of Q3 2025.

  • Centiva Capital reported no remaining ADMA Biologics position as of Q3 2025 after selling out during the quarter.
  • Centiva Capital sold 11,065 ADMA Biologics shares in Q3 2025, an estimated $201K.
  • Centiva Capital first reported a position in ADMA Biologics in Q4 2024 and held it in 3 quarters.
  • Centiva Capital's ADMA Biologics position peaked at $351K in Q1 2025.
  • 365 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2025.

Based on Centiva Capital's 13F filing for Q3 2025, filed 14 Nov 2025.